Pipeline | Handok

Therapeutic Area

Area	Project (Originator)	Category	Indication	Remarks
Rare / Metabolic	RZ358 (Rezolute)	Biologic	Congenital Hyperinsulinism	Handok: Korea commercialization rights Did not achieve statistical significance vs. placebo FDA Type B meeting completed based on sunRIZE and OLE data (Q1 2026)
	RZ358 (Rezolute)	Biologic	Tumor Hyperinsulinism	Handok: Korea commercialization rights Phase 3 topline results expected (H2 2026) June 2026 interim analysis: primary endpoint met in 6 of 8 patients and efficacy confirmed
	HL2356 (GX-H9) (Genexine)	Biologic	Pediatric Growth Hormone Deficiency	Handok: Preparing for domestic approval Partner, TJ Biopharma: China product approval process in progress
	HL2356 (GX-H9) (Genexine)	Biologic	Adult Growth Hormone Deficiency
Oncology	HD-B001A (ABL Bio)	Biologic	Solid Cancer (BTC)	Handok: Korea commercialization rights Partner, Compass Therapeutics: Phase 2 data, including PFS and OS, announced (Q2 2026)
	ABL111 (ABL Bio)	Biologic	Solid Cancer	Handok: Korea development and commercialization rights NovaBridge Biosciences: Efficacy and safety demonstrated in GC Phase 1b Phase 3 initiation expected in December 2026 based on FDA consultation
	ABL503 (ABL Bio)	Biologic		Handok: Korea right of first negotiation Partner, ABL Bio: Phase 1 ongoing
	SBP-101 (Spark Biopharma)	NCE		Handok: Korea commercialization rights Partner, Spark Biopharma: Phase 1a ongoing
	HD-NC003	NCE
	HD-NC004	NCE		Selected for a Ministry of Trade, Industry and Energy R&D project for new drug development in non-small cell lung cancer

Digital Health

Area	Project	Category	Indication	Remarks
CNS	WELT – I (SleepQ)	DTx	Insomnia	Handok: Korea market development and commercialization rights SleepQ digital therapeutic for insomnia launched
	WELT – A		Alcoholism	Handok: Korea market development and commercialization rights
	WELT – ED		Eating Disorder	Handok: Right of first review for Korean market